Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study-Reference-Cited by-同舟云学术

Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study

Published:2018-10 Issue:15 Volume:19 Page:1169-1179
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Tonozzi Theresa R¹,Braunstein Glenn D¹,Kammesheidt Anja¹,Curran Chris²,Golshan Shahrokh³,Kelsoe John³

Affiliation:

1. Pathway Genomics, San Diego, CA 92121, USA

2. Patients Like Me, Cambridge, MA 02142, USA

3. Department of Psychiatry, University of California, San Diego, CA 92093, USA

Abstract

Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications. Methods: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing. Results: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time. Conclusion: Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2018-0088

Reference24 articles.

1. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief #76. National Center for Health Statistics, MD, USA (2011). https://www.cdc.gov/nchs/data/databriefs/db76.pdf.

2. Peterson K, Dieperink E, Ferguson L, Anderson J, Helfand M. Evidence Brief: The Comparative Effectiveness, Harms, and Cost-effectiveness of Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder. VA Evidence-based Synthesis Program Evidence Briefs. Department of Veterans Affairs, Washington, DC, USA (2016). https://www.ncbi.nlm.nih.gov/books/NBK384610/.

3. Genetics and pharmacogenetics of mood disorders

4. Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors

5. Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Online Health Communities: an alternative feasible data registry tool for developing countries;Health Research Policy and Systems;2023-04-06

2. Pharmacogenetics of antipsychotics: Clinical utility and implementation;Behavioural Brain Research;2021-03

3. Determination of nine mental drugs in human plasma using solid-phase supported liquid-liquid extraction and HPLC-MS/MS;Microchemical Journal;2021-01

4. Promoting Tech Transfer Between Space and Global Mental Health;Aerospace Medicine and Human Performance;2020-09-01

5. Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection;International Journal of Bipolar Disorders;2020-07-04